Lv21
184 积分 2023-06-19 加入
Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial
5小时前
已完结
Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial
5小时前
已完结
Long‐term immunogenicity and safety of heterologous boosting with a SARS‐CoV‐2 mRNA vaccine (SYS6006) in Chinese participants who had received two or three doses of inactivated vaccine
5小时前
已完结
〈1040〉 Quality Considerations of Plasmid DNA As A Starting Material for Cell and Gene Therapies
14天前
已关闭
Regulatory considerations for nucleic acid vaccines
14天前
已完结
Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA
15天前
已完结
Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering
15天前
已完结
The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
16天前
已完结
Low endotoxin recovery and its impact on endotoxin detection
23天前
已完结
Lyophilized Drug Product Cake Appearance: What Is Acceptable?
1个月前
已完结
皖公网安备34019202002308
